HSA
IOVA icon

HBK Sorce Advisory’s Iovance Biotherapeutics IOVA Stock Holding History

HBK Sorce Advisory’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,027
Closed -$38K – 681
2025
Q4 		$38K Buy
15,027
+1,199
+9% +$2.77K ﹤0.01% 616
2025
Q3 		$31K Buy
13,828
+2,198
+19% +$5.19K ﹤0.01% 612
2025
Q2 		$20K Buy
+11,630
New +$28.9K ﹤0.01% 586

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

HBK Sorce Advisory's IOVA Position: Q1 2026 in Review

HBK Sorce Advisory sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 15,027 shares — an estimated $38K sold.

HBK Sorce Advisory first reported a position in IOVA in Q2 2025 and held it in 3 quarters. The position peaked at $38K in Q4 2025. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • HBK Sorce Advisory reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • HBK Sorce Advisory sold 15,027 Iovance Biotherapeutics shares in Q1 2026, an estimated $38K.
  • HBK Sorce Advisory first reported a position in Iovance Biotherapeutics in Q2 2025 and held it in 3 quarters.
  • HBK Sorce Advisory's Iovance Biotherapeutics position peaked at $38K in Q4 2025.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on HBK Sorce Advisory's 13F filing for Q1 2026, filed 11 May 2026.